Revolutionary Breakthrough: PCL’s Groundbreaking Early Dementia Diagnosis Technology Secures Russian Patent
- PCL has announced the successful registration of a patent for the 'Development of a high-sensitivity Alzheimer's diagnosis kit using a new marker and a human mini-brain in vitro...
- This innovative technology was developed through an international joint technology development project with Geneva Hospital in Switzerland and Newrix.
- The patented technology involves a novel biomarker for diagnosing Alzheimer's disease derived from exosomes and a 'method for providing information for diagnosing Alzheimer's disease' including a composition for...
Geneva Hospital, Switzerland, and Newrix Collaborate on Groundbreaking Alzheimer’s Diagnosis Kit
PCL has announced the successful registration of a patent for the ‘Development of a high-sensitivity Alzheimer’s diagnosis kit using a new marker and a human mini-brain in vitro screening platform’ with the Russian Patent Office.
This innovative technology was developed through an international joint technology development project with Geneva Hospital in Switzerland and Newrix. According to WHO research data, the need for early diagnosis technology for dementia is becoming increasingly important, particularly in Russia, where the population is aging and dementia-related deaths are on the rise.
The patented technology involves a novel biomarker for diagnosing Alzheimer’s disease derived from exosomes and a ‘method for providing information for diagnosing Alzheimer’s disease’ including a composition for diagnosing Alzheimer’s disease and the biomarker. By utilizing this biomarker, the accuracy, sensitivity, and specificity of Alzheimer’s diagnosis can be significantly increased through a detailed diagnosis according to the progression stage of the disease.
Compared to the existing ELISA immunoassay method, which has limited detection capabilities and only allows for one test per well, PCL’s technology offers several advantages. By using protein immobilization technology (SG Cap) with sol-gel, the company’s core technology, PCL has increased sensitivity and specificity while also enabling multiple diagnoses by allowing up to 64 different markers to be fixed in spot format per well.
PCL CEO Kim So-yeon emphasized the significance of this patent, stating that it offers an effective technology for reducing the social cost of dementia by enabling early diagnosis and facilitating the most appropriate and cost-effective use of various treatments. This technology is particularly well-suited for the aging world population.
Medical Today Reporter Nam Yeon-hee